Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
95 Leser
Artikel bewerten:
(0)

Biopharmaceutical CMO & CRO Market to Value $37.8 Billion by 2025: Regional Estimates & Trend Analysis, by Service, Source, & Product

DUBLIN, August 18, 2017 /PRNewswire/ --

The "Biopharmaceutical CMO & CRO Market, 2014 - 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global biopharmaceutical CMO & CRO (contract manufacturing & research) market is expected to reach USD 37.8 billion by 2025, according to this new report.

Healthy outlook of biopharmaceuticals and consequent growth in biopharmaceutical pipelines has resulted into lack of adequate capacity and budget constraints. These factors have convinced many traditional drug developers to take advantage of cost-saving benefits associated with contract services. Traditional biopharmaceutical players are observed to choose outsourcing biopharmaceutical manufacturing rather than making an investment of expensive capital in production equipment and hiring skilled labor.

Significant improvement in the services offered by this CMOs/CROs in context to maturity of complex technology is spurring the adoption of these services. In addition, wide acceptance of single-use technology within CMOs/CROs has significantly transformed the CMOs/CROs landscape by enhancing their capabilities and enabling them to develop products at low operating costs.

Outsourcing services are observed to play critical role in overcoming trade barriers for firms. It enables them to make footprints in foreign market where government regulates to secure local employment through domestic production. Furthermore, as a result of growing demand for these services, smaller companies have also begun to expand their non-GMP facilities.

Companies Mentioned

  • Boehringer Ingelheim GmbH
  • LONZA
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • CELONIC AG
  • BIOMEVA GmbH
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • TOYOBO CO., LTD.
  • Samsung BioLogics
  • Patheon
  • DPx
  • CMC Biologics
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Market Variables, Trends & Scope

4. Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis

5. Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend Analysis

6. Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis

7. Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Service, Source, & Product

8. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/m6q67t/biopharmaceutical

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.